key: cord-0831750-w9bre10h
authors: Faqihi, Fahad; Alharthy, Abdulrahman; Karakitsos, Dimitrios
title: Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome
date: 2020-07-13
journal: J Formos Med Assoc
DOI: 10.1016/j.jfma.2020.07.016
sha: d66e0deb5e5eaf1656353b60ed9966da384340c7
doc_id: 831750
cord_uid: w9bre10h

nan

We read with interest the report by Lin et al. that was recently published in the journal. 1 The authors are to be congratulated for their excellent work. Our group's interest about the putative benefit of therapeutic plasma exchange (TPE) in critically ill patients with SARS-CoV-2 disease (COVID-19) has been documented. 2 In a minority of patients, COVID-19 can present with lifethreatening features such as acute respiratory distress syndrome (ARDS), septic shock, thromboembolic disease, multi-system organ failure, and associated cytokine release syndrome (CRS). The latter is defined by criteria outlined in Table. TPE can be performed with a variety of adsorption cartridges and has been the subject of well-known clinical trials. 5 Although SARS-CoV-2 is a respiratory virus, COVID-19 can be interpreted as a clinical syndrome with various cardiovascular, neurological, hematological and other manifestations. The suppression of CRS may be a key therapeutic step in the management of critically ill COVID-19 patients. Reducing cytokines, especially interleukin-6, warrants further attention. A monoclonal antibody against iterleukin-6 (tocilizumab) has been recently used in COVID-19 but with conflicting results. The benefit of TPE is still uncertain in severe ARDS due to COVID-19. Also, the natural course of SARS-CoV-2's viremia remains obscure.

Hence, the relationship between viral RNA reduction and TPE, and the standardization of the TPE regime need to be further investigated.

No financial support was received for this study.

The study was approved by our Institutional Review Board (protocol/serial number: H-01-R-053, IORG0010374, H1R1-20-01TYGH-109-05).

All authors have no conflicts of interest relevant to this article.

Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19

A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol

Cytokine release syndrome in severe COVID-19

download: D2000 Cartridge Operation Manual for Use of D2000 with the Terumo Spectra Optia™ Apheresis System; for use in the U.S. under FDA EUA200148: Authorization for Emergency Use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Abbreviations: CRS = cytokine release syndrome, LDH = lactate dehydrogenase; * We define as low risk for developing CRS the presence of one criterion, moderate risk the presence of two to three criteria and high risk the presence of more than three criteria